Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Equity Income (2022 - 2024)

Historic Equity Income for Caribou Biosciences (CRBU) over the last 3 years, with Q3 2024 value amounting to -$14000.0.

  • Caribou Biosciences' Equity Income fell 25000.0% to -$14000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was -$125000.0, marking a year-over-year decrease of 11929.82%. This contributed to the annual value of -$6000.0 for FY2023, which is 9548.87% up from last year.
  • Caribou Biosciences' Equity Income amounted to -$14000.0 in Q3 2024, which was down 25000.0% from -$102000.0 recorded in Q2 2024.
  • Caribou Biosciences' 5-year Equity Income high stood at $31000.0 for Q3 2022, and its period low was -$102000.0 during Q2 2024.
  • In the last 3 years, Caribou Biosciences' Equity Income had a median value of -$14500.0 in 2023 and averaged -$25500.0.
  • Its Equity Income has fluctuated over the past 5 years, first surged by 23750.0% in 2023, then crashed by 56363.64% in 2024.
  • Quarter analysis of 3 years shows Caribou Biosciences' Equity Income stood at -$60000.0 in 2022, then soared by 85.0% to -$9000.0 in 2023, then tumbled by 55.56% to -$14000.0 in 2024.
  • Its last three reported values are -$14000.0 in Q3 2024, -$102000.0 for Q2 2024, and -$9000.0 during Q4 2023.